Elin M Svensson

List of Publications by Year
in descending order

58 papers	1,322 citations	331670 21 h-index	395702 33 g-index
60 all docs	60 docs citations	60 times ranked	1058 citing authors

#	Article	IF	Citations
1	Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics. Clinical Microbiology and Infection, 2022, 28, 448.e1-448.e7.	6.0	7
2	Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease. Chest, 2022, 161, 370-372.	0.8	5
3	Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Journal of Clinical Pharmacology, 2022, 62, 385-396.	2.0	4
4	Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Clinical Infectious Diseases, 2022, 75, 141-151.	5.8	16
5	Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment. Antimicrobial Agents and Chemotherapy, 2022, , AAC0174921.	3.2	1
6	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. Journal of Infectious Diseases, 2022, 226, 147-156.	4.0	8
7	Drug concentration at the site of disease in children with pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1710-1719.	3.0	3
8	Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis. Expert Review of Clinical Pharmacology, 2022, 15, 161-174.	3.1	1
9	Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1228-1235.	5.6	17
10	Assessing Prolongation of the Corrected QTÂInterval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac SafetyÂof Simplified Dosing Regimens. Clinical Pharmacology and Therapeutics, 2022, 112, 873-881.	4.7	10
11	Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical Pharmacokinetics, 2022, 61, 1177-1185.	3.5	7
12	Pharmacometrics in tuberculosis: progress and opportunities. International Journal of Antimicrobial Agents, 2022, 60, 106620.	2.5	3
13	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies. European Journal of Clinical Pharmacology, 2021, 77, 727-733.	1.9	2
14	Constructing a representative inâ€silico population for paediatric simulations: Application to HIVâ€positive African children. British Journal of Clinical Pharmacology, 2021, 87, 2847-2854.	2.4	15
15	A population pharmacokinetics analysis assessing the exposure of raltegravir onceâ€daily 1200Âmg in pregnant women living with HIV. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 161-172.	2.5	1
16	Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. Clinical Pharmacokinetics, 2021, 60, 649-654.	3.5	7
17	A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. Clinical Pharmacokinetics, 2021, 60, 943-953.	3.5	5
18	Increased bactericidal activity but dose-limiting intolerability at 50â€…mgÂ·kg^{â^'1} rifampicin. European Respiratory Journal, 2021, 58, 2000955.	6.7	32

#	Article	IF	Citations
19	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clinical Pharmacokinetics, 2021, 60, 685-710.	3.5	39
20	High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases, 2021, 73, 876-884.	5.8	40
21	Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0268720.	3.2	16
22	The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. Frontiers in Pharmacology, 2021, 12, 637618.	3.5	4
23	An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies. Antimicrobial Agents and Chemotherapy, 2021, 65, e0273020.	3.2	3
24	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0239920.	3.2	10
25	Pharmacometrics meets statisticsâ€"A synergy for modern drug development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1134-1149.	2.5	9
26	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 3237-3246.	3.0	26
27	Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa. Parasites and Vectors, 2021, 14, 524.	2.5	1
28	Exposureâ€"safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drugâ€resistant tuberculosis. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1538-1549.	2.5	21
29	Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. Clinical Infectious Diseases, 2020, 71, 1817-1823.	5.8	47
30	Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing. Clinical Infectious Diseases, 2020, 71, 3055-3060.	5.8	11
31	Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?. Journal of Antimicrobial Chemotherapy, 2020, 75, 609-617.	3.0	34
32	Understanding the drug exposureâ€"response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrugâ€resistant tuberculosis. British Journal of Clinical Pharmacology, 2020, 86, 913-922.	2.4	13
33	Clofazimine pharmacokinetics in patients with TB: dosing implications. Journal of Antimicrobial Chemotherapy, 2020, 75, 3269-3277.	3.0	33
34	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 3433-3457.	3.0	23
35	The pharmacokinetics of paraâ€aminosalicylic acid and its relationship to efficacy and intolerance. British Journal of Clinical Pharmacology, 2020, 86, 2123-2132.	2.4	14
36	Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens. European Journal of Clinical Pharmacology, 2020, 76, 1557-1565.	1.9	2

#	Article	IF	Citations
37	Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	13
38	A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. Journal of Antimicrobial Chemotherapy, 2019, 74, 935-943.	3.0	72
39	Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin. Clinical Pharmacokinetics, 2019, 58, 815-826.	3.5	25
40	Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Clinical Pharmacokinetics, 2019, 58, 1103-1129.	3.5	50
41	Protein binding of rifampicin is not saturated when using high-dose rifampicin. Journal of Antimicrobial Chemotherapy, 2019, 74, 986-990.	3.0	13
42	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	11
43	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	6
44	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clinical Infectious Diseases, 2018, 67, 34-41.	5.8	80
45	Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. Journal of Infectious Diseases, 2018, 218, 991-999.	4.0	54
46	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 2018, 57, 591-599.	3.5	26
47	Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. British Journal of Clinical Pharmacology, 2018, 84, 2384-2392.	2.4	23
48	Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 26-29.	1.2	17
49	Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 212-217.	2.5	38
50	Modelling of mycobacterial load reveals bedaquilineâ€™s exposureâ€“response relationship in patients with drug-resistant TB. Journal of Antimicrobial Chemotherapy, 2017, 72, 3398-3405.	3.0	46
51	Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drugâ€Resistant Tuberculosis: The Effect of Timeâ€Varying Weight and Albumin. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 682-691.	2.5	54
52	Pharmacokinetic Interactions for Drugs with a Long Half-Lifeâ€”Evidence for the Need of Model-Based Analysis. AAPS Journal, 2016, 18, 171-179.	4.4	23
53	Population pharmacokinetic drugâ€“drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy, 2016, 71, 1330-1340.	3.0	10
54	Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. Journal of Antimicrobial Chemotherapy, 2015, 70, 1106-1114.	3.0	98

#	Article	IF	Citations
55	Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection. Antimicrobial Agents and Chemotherapy, 2014, 58, 6406-6412.	3.2	57
56	Use of a linearization approximation facilitating stochastic model building. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 153-158.	1.8	5
57	Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2780-2787.	3.2	85
58	Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. British Journal of Clinical Pharmacology, 2012, 74, 465-476.	2.4	24